888.2500 0.20 (0.02%)
NSE Apr 30, 2025 15:31 PM
Volume: 907.5K
 

KRChoksey
In Q3FY23, ZYDUSLIF reported strong growth across businesses. The company’s key markets i.e. India and the US, have reported double digit growth of 12.5% and 29.3% respectively. The Indian business revenue was at INR 16436mn up 13% YoY. The Indian formulation business registered revenues of INR 12316mn and contributed around 30% of consolidated revenues (excluding COVID related issues).
Zydus Lifesciences L.. has an average target of 1052.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended